Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

biotech_invest 154 posts  |  Last Activity: 8 hours ago Member since: Mar 5, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biotech_invest biotech_invest 8 hours ago Flag

    well, I'll specially repeat it again for you, naive da_ :-) If you know what is going on in science (both academy and industry) you will never believe in published results and invest in biotechs like PRAN, ORMP, AXON, BLUE etc.
    Do you really think that scientists never lie and never publish faked researches? Naive and stupid dilettante :-)
    Just read this paper "In science, irreproducible research is a quiet crisis"
    One key citation from this paper:
    "Scientists at Bayer HealthCare reported that when they tried to reproduce 67 published discoveries in oncology, women’s health, and cardiovascular disease, only a quarter of the time were their in-house results completely consistent with what had been reported. A scientist at Amgen disclosed that, despite concerted effort, the company had successfully repeated only six of 53 major cancer findings." In simple words only 25% (best case scenario) of papers published in in reputable journals is real results. Other 75% are faked researches.
    With such statistics 75% of "dozens and dozens of research papers authored by non-Prana, non-Tanzi related scientists in reputable journals" are lies and faked research. Is it enough for you, naive dilettante? I'm working in science all my life and know what is going on in this dirty kitchen. So, when I'm "solving" biotech companies i.e. want to know what they are scams or gems I never believe in their published papers or website advertisement. I'm just "cracking the nut" i.e. analyse all available data about the technology/method/approach that they claim as pivotal. Usually there is one of 2 possible answers: SCAM or GEM. PRAN is in Biotech scam list (read here why (wwwDOTbiotechinvestDOTnet/pran_scam.html)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest May 4, 2016 11:42 AM Flag

    Wow! We have some so respectful person here that everybody should follow his advises :-)
    Of course, imtom9930 mostly use only one word on this MB (Dope) but his credentials are just enormous. He knows practically everything about AD, HD, PD and other diseases.
    So, imt, as usually you are advising to hold PRAN and add more. Very wise advise :-)
    May be any other strategy? Like sell everything now, wait for low and they buy?
    Nope. Only STRONG BUY
    Sure that that this senile idiot will continue it as a parrot even when PRAN pps deep to $3 and below in next month :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest May 4, 2016 11:21 AM Flag

    kad, may be you are right about 100% pps spike right after PCH lift (of course only with 250 mg PBT2 daily). So, it will be $6 from current (or $1 in before 1:6 RS price).
    But what will happen after this spike? Yep, PRAN will become Ph3 small cap biotech and this Ph3 is for HD. But when we know about Ph3 HD results? Best case scenario: 2020. Ph3 is very expensive trial so PRAN needs more money. Since there are no partners they will do stock dilutions. And both current holders and buyers at spike pps ($5-6) will have huge losses.
    Of course, PRAN pumpers like you will start promising partners, upfront money etc. but it's ugly lie. Big Pharma usually sniffs all good technologies and drugs long time before Ph3 stage. If they not contact with PRAN before and now you can make very simple conclusion: they are not interesting in PBT2 and other PRAN fake drugs. They know it will be waste of money and time to invest money in library metal chelators that will cure AD, HD, PD etc.
    So, what will happen next after possible 100% pps spike induced by PCH lift?

    Sentiment: Strong Sell

  • Let's remember the whole story of PCH for PRAN PBT2 that started Feb 13, 2015 or almost 15 months ago:
    "FDA has placed PRAN Phase 3 clinical trial evaluating PBT2 in Huntington's disease (HD) on partial clinical hold based on findings from animal tests. This significantly limits the dose of PBT2 that can be given to HD patients, although the agency has not raised any concerns about the PBT2 safety data in human trials so far.The company's options are to proceed with the Phase 3 trial at a dosage level that is not considered clinically relevant (unlikely) or to conduct additional animal neurotoxicity studies or identify a strategy for safely using a clinically relevant dose of PBT2 in humans in its planned Phase 3 HD study."
    So, lower dose is definitely 100 mg PBT2 daily and "clinically relevant dose" is 250 mg PBT2 daily that can be potentially neurotoxic for HD patients.
    1) Easiest way to lift PCH is agree to dose only 100 mg (PRAN keeps it as emergency variant);
    2) conduct additional animal neurotoxicity studies is dangerous approach because it can bring bad results for Prana;
    3) identify a strategy for safely using a clinically relevant dose of PBT2 in humans in its planned Phase 3 HD study - they must persuade FDA that any toxic effects of PBT2 in HD patients will be immediately revealed by Independent Monitoring committee and trial will be stopped before it's too late (last case is CARA pain killer at high doses).
    15 months is enough to do animal studies but it's very unlikely that PRAN even started it.
    So, the identification a strategy and may be design special protocol for monitoring and identification of potential neurotoxic effects in HD patients looks like the most feasible approach for PRAN. Problem that it's not easy to monitor some neurotoxic effects of drug in HD patients because Huntington's disease (HD) is a neurodegenerative genetic disorder.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest May 3, 2016 10:58 AM Flag

    as usually eso is making some delusional statements :-) only naive investors will believe in idea that PRAN can start Ph3 HD in different countries if FDA finally reject dosing regiment 250 mg PBT2 daily because of potential neurotoxicity for HD patients.
    I think PRAN plan was simple here: postpone the sending a Complete Response to FDA as long as they can and then agree with 100 mg PBT2 daily dosing. Indeed, it's better be Ph3 stage small cap biotech than scam biotech without any outgoing clinical trials. PRAN management just need some longer time so many holders and investors will forget that PBT2 was barely effective with 250 mg and absolutely non-effective at 100 mg PBT2 daily.
    They know that pps will retreat in case of "100 mg" scenario but they know "magic" of being Ph3 HD small cap biotech. Especially if they hire analysts and bloggers that will say that with big number of patients even 100 mg PBT2 daily can show some improvement in HD patients. They just want 4-5 years more of happy life :-)
    Question for PRAN pumpers: will you support PCH lift with 100 mg PBT2 daily? Sure, they will :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest May 2, 2016 10:11 PM Flag

    LOL! eso, I never said that I'm smarter than Tanzi :-) I'm just said that his "metal theory of AD" is stupid and will never lead to effective AD drug. And Ph2 AD with PBT2 showed it clearly. Only stupid and stubborn people will continue singing panegyrics to Tanzi and believe that this guy will cure AD, HD or PD patients. Tanzi is smart enough to fool people like you. But he is not smart enough to fool Big Pharma scientists and persuade them to make partnership for PBT2 studies. And look at PRAN % of institutional ownership - it's laughable 1% :-)
    About PRAN shorting: I said it's safe to short right after notification about 1:6 RS when pps was $3.84. Today pps is $3.85 so shorts lose practically nothing. Is it safe to keep short positions now when May is here and many investors are selling for summer time? Why not?
    Even lift of PCH with 250 mg PBT2 daily will not induce big pps spike. Ph3 HD will take years and at the best case scenario we will know the results in 2020. Dead money for 4 years.
    BTW TauRx drug can be also effective for HD and if Ph3 AD is successful investors will believe in TauRx future but not in PRAN fake drug.
    So, keep Tanzi as...kissing :-) You are doing it professionally :-)

    Sentiment: Strong Sell

  • it means that they don't have any strong proof that PBT2 250 mg daily dosing will not be toxic for HD patients. They avoided NASDAQ delisting by 1:6 RS but they can't stop pps crash without PCH lift. However, they can again fool holders by starting Ph3 HD with 100 mg PBT2 daily dosing. They know that PRAN holders will not sell even with this terrible scenario :-) They will hold PRAN before bankruptcy :-)
    14 months is more than enough for combining of all safety data to a Complete Response. Most likely that PRAN is just waiting and hoping that everybody will forget that PBT2 100 mg daily was useless for HD (250 mg was also useless but small group statistical noise allowed to get them some "positive" change).
    Well, let's wait and monitor this scam.

    Sentiment: Strong Sell

  • Reply to

    More about Tau in HD

    by pivalde May 2, 2016 3:30 PM
    biotech_invest biotech_invest May 2, 2016 5:09 PM Flag

    LOL! Do you think that you or other PRAN pumpers like you have any credibility here? Actually, no one anonymous poster can have any credibility here. Why anybody believe in your posts? May be you are just a janitor that wanted to win by investing in PRAN scam? Now you have -95% losses and think that your posts can reverse pps decline.
    You can't even prove that you have some brain. Just one from group of stupid and annoying PRAN pumpers that admiring and as...kissing Tanzi. Some of you are pretending that they are scientists, citing papers here and thinking that in such way they can help PRAN to stop pps decline. But pps is still at historical low and only 1% of outstanding shares is owned by funds/institutions. And there is no line from Big Pharmas that want to partner "ingenious" PRAN technology :-)
    Look at BIND: just one month ago pps was $2.50 but today after filing Chapter 11 pps is $0.38. They had collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co. and cash, cash equivalents and short-term investments were $36.9 million as of December 31, 2015.
    PRAN has no partners and money is slowly evaporating. They continue fooling stockholders and investors during last 14 months by promising to PCH for Ph3 HD with PBT2 250 mg daily dose. Most likely that after 1.5 year they will notify holders that they will start Ph3 HD with 100 mg PBT2 daily. And again you, stupid PRAN pumpers, will continue to lie here that PBT2 is so good and strong drug that even at 100 mg will cure HD.

    Sentiment: Strong Sell

  • Reply to

    More about Tau in HD

    by pivalde May 2, 2016 3:30 PM
    biotech_invest biotech_invest May 2, 2016 3:42 PM Flag

    looks like that you switched to tau as a main player in HD etiology :-) Why so high attention? Want to link PBT2 to HD mechanisms?
    But the cited paper is good (especially if you understand the results) so you got my thumb up for this. So, if TauRx anti-tau-aggregation compound shows good results in AD Ph3 they should definitely test it for HD.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 29, 2016 1:13 PM Flag

    still believe that Tanzi will bring you AD/HD/PD drug, senile idiot? After 5-6 years Tanzi will retire with very good retirement money. Most of this money he got from AD funds and from PRAN scam i.e. from stupid and naive holders like you.
    BTW, July is very close now may be we will see some real AD drug very soon. If TauRx drug really slow down cognition decline 80-90% in comparison with placebo arm, everybody will forget about stupid "metal theory of AD" and PBT2.
    Sure, you will continue bet on HD and PD. But TauRx drug can be also active against HD and PD
    "TauRx has composition of matter patents and use patents covering the application of its TAIs for the treatment and prevention of Alzheimer’s and FTD. The company is also exploring the use of TAIs in several other neurodegenerative diseases associated with tau pathology, as well as other disorders deriving from the aggregation of other proteins in the brain, including Parkinson’s and Huntington’s."

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 29, 2016 11:40 AM Flag

    And where are all my posts that were responses to most active Tanzi as...kissers? Some idiot had blamed me that I'm erasing the posts here but I see now a clear evidence that someone from your band is deleting my posts. So, now under this topic we have very nice conversation and panegyrics to Tanzi. Well, continue your as...kissing process, it will not help to fool investors. They already know that PRAN is scam biotech. You should be very careful when you want make money on scams.

    Sentiment: Strong Sell

  • What was actual goal of this trial?
    The answer is “overall Pain Relief and Safety of Intravenous (IV) CR845
    CR845 will be administered intravenously prior to surgery, and at specific time intervals post surgery: CR845 IV 1 mcg/kg will be administered as an IV bolus one hour prior to anesthetic induction for surgery, again within 30 minutes of the patient being considered stable in the post operative recovery room, then 2 hours following that Baseline dose. Subsequent dosing will be administered at 6, 12 and 18 hours after the Baseline dose. Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.
    Drug: Placebo IV
    Placebo IV will be administered as an IV bolus one hour prior to anesthetic induction for surgery, again within 30 minutes of the patient being considered stable in the post operative recovery room, then 2 hours following that Baseline dose.
    Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.
    Definitely, main goal of CR845 administration is a decreasing of usage of analgesic medication like morphine by patients after abdominal surgery. Morphine is a narcotic; so many patients can become addictive after several injections. So, less injections of morphine is better.
    Some skeptics will say that Ph3 trial will fail primary goals because CR845 doses 0.5 and 1 ug/kg are too low to provide strong analgesic effect but it’s not true: 6 injections each 1 ug/kg will give CR845-treated patient
    with 80 kg weigh almost 500 ug of strong analgesic during 18 hours. It’s more than enough to decrease pain and decrease (if any) morphine injections during 18 hours. 0.5 ug/kg also will give 250 ug per 18 hours and also should decrease number of morphine injections.
    Read here entire story (wwwDOTbiotechinvestDOTnet/cara.html)

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Apr 27, 2016 12:34 PM Flag

    It was easy to predict that Bapi will fail because all AD drugs that fight with Abeta (directly or indirectly as secretase inhibitors ) failed and will fail in clinical trials. Now Eli Lilly has a clinical trial for the Alzheimer’s drug solanezumab and again this idiot Selkoe is backing it. 90% probability that Sola will also fail to decrease a cognition decline.
    So, even dilettantes can predict this failure.
    But what about TauRx AD drug that fight not with Abeta but only with tau aggregation? What is your prediction for LMTX®?
    I have assumed that resent NOVA show about AD cures never even mentioned LMTX® as a potential breakthrough in AD treatment.
    Any guess like 70%, 90% of failure of LMTX®?
    If you are claiming that you are not a dilettante in science and in neuroscience your prediction should be correct. And we will know was you right or not may be already in a couple of months.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 27, 2016 11:25 AM Flag

    kad, why do you think that I have more than one ID? Actually it's the same ID as my website and twitter and hundreds investors are reading my comments there. I'm posting not only on PRAN MB and not only on MB of scam biotechs. But usually I provide a link to my website or twitter so people can read real comments.
    About MPACs safety: I think FDA worries about long-time exposure toxicity for PBT2 250 mg daily doses. In Ph3 HD big group of patients will have PBT2 250 mg daily during at least 52 weeks. PBT2 is close by structure to 8-Hydroxyquinoline or to 5-Chloro-7-iodo-quinolin-8-ol (Clioquinol). Last one is a halogenated 8-hydroxyquinoline that was used in 1950-1970s as an oral anti-parasitic agent for the treatment and prevention of intestinal amebiasis. However in the 1970s oral Clioquinol was withdrawn from the market due to reports of neurotoxicity in Japanese patients.
    Do you really think that FDA wants any problems like potential PBT2 neurotoxicity in HD patients? If they see even negligible possibility of neurotoxicity with 250 mg PBT2 daily they will never allow such dosing.
    Recently FDA put on hold CARA Ph3 because four patients in the highest CR845 dose group (5 ug/kg) exhibited transient serum sodium levels equal to or greater than 150 mmol/L (mild-to-moderate hypernatremia). But why CR845 high doses induces hypernatremia? The answer is simple: CR845 is a peripherally acting kappa opioid receptor agonist. And it is known that "kappa-opioid receptor agonists inhibit antidiuretic hormone secretion and promote water excretion in humans and experimental animals" (you can read all story here (wwwDOTbiotechinvestDOTnet/cara.html) if you are interesting.
    CARA removed high doses 2-5 ug/kg and FDA lifted trial hold. Most likely PRAN will do the same: go to Ph3 HD with 100 mg PBT2 daily. It will be terrible for pps.

    retention and dilutional hypona

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 26, 2016 10:18 PM Flag

    Oopsy :-) Almost all my guinea pigs swallowed the bait :-) You are so predictable, my stupid naive PRAN pumpers :-) Please, be here for next 2-3 years - I'll continue my funny experiments with you :-)
    Good night, my funny pack, sleep tight :-)

    Sentiment: Strong Sell

  • pivalde, long_ranger213, bobmenji1, interesting2me, g2nosis....
    Altogether more than 10 IDs but most likely 1-2 real persons. Most likely PRAN employees that hope for pps spike to realize their options. Sorry for your losses guys, but you will never see your money again :-)
    All your promises are lie and you already know that PRAN can't lift PCH without animal tox studies. You just want to induce some run up before pps crash.
    Well, good job, naive idiots!

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 26, 2016 4:38 PM Flag

    kad, fortunately you don't know what is going in this dirty kitchen :-) Good for you, naive dilettante :-) If you know you will never invest in biotechs. Looks like you believes in all published results because only honest scientists can do the peer reviewing. Investors like you put money in scams like BIOD, AXON, ORMP, NNVC, AVXL, PRAN and then they are crying that they lose money. Each biotech is a puzzle and it needs to be solved before investing. If you believe in everything what they claim you will lose all your money here.
    BTW, I had never said that they can't fool me. For example NNVC fooled me and one time I was thinking that they have real breakthrough in anti-viral treatment. Now NNVC in my Biotech scam list. Just it's less probability that they can fool me. Because I don't care about names, titles etc. Names of Tanzi, Shoulson or any somebody else mean nothing for me.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 26, 2016 4:07 PM Flag

    LOL! Your attempts to humiliate me are just pitiful :-)
    What do you know about science, poor dilettante? All PRAN pumpers have one very common thing: they are all Tanzi admirers and as...kissers :-) May be we have only one person who using multiple IDs. BTW why you stop using rkf ID? We are missing Rough Kansas Farter so much :-) His/her anxiety and stupidity were so funny :-)
    So, continue sipping your stool, idiot :-) Hope you are really PRAN holder so you will have your stool very liquid when PRAN pps crashed below $1.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 26, 2016 3:11 PM Flag

    And what exactly these 2 old farters know? Definitely they know how to fool naive investors like you that are dilettantes in science :-) Did they cure at least 1 AD or HD patient? Nope. What the losses have PRAN holders that believed them (mostly Tanzi) and bought PRAN in 2010-12 for $10-12 (in current price)? 70%
    Buyers before Ph2 AD crash got 95% losses. LOL! And they still believe that Tanzi and Shoulson know something?
    You and your cronies want to fool investors again and buy PRAN now. You are promising crazy pps spike to $15-20 after PCH lift. But most likely $4 buyers will have 50% losses very soon. And you will again promise a new spike.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 26, 2016 3:00 PM Flag

    well, May is coming :-) Only idiots like you will keep this scam during summer time. So, keep and wait. In July PRAN will celebrate 1.5 year of PCH for Ph3 HD. And of course they will keep saing that they continue to work with FDA to lift PCH. Just ugly lie! It was more than enough 1 year to prepare Complete Response and lift PCH. They have nothing to send in FDA. They know that dog studies with dose equal to human 250 mg daily will show PBT2 toxicity. So, most likely that they will agree to start Ph3 HD with 100 mg PBT2. Just wait more time: may be some investors and holders will forget that PBT2 100 mg daily was absolutely non effective.

    Sentiment: Strong Sell

SNY
39.07+0.32(+0.83%)May 5 4:01 PMEDT